Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

Press Release Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on ...

With so much at stake, nature keeps it tightly controlled in a process called the cell cycle that scientists thought they thoroughly understood. But now it turns out there was more to know. Scientists ...

Circle Pharma to present late-breaking poster at AACR highlighting new mechanistic ... key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL ...

BioAtla (BCAB) announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin, a Conditionally Binding CAB-ROR2-ADC, in Patients with ...

2-DE Analysis of Breast Cancer Cell Lines MDA-1833 and MDA-4175 with Distinct Metastatic Organ-Specific Potentials and Comparison with Parental Cell Line MDA-MB-231 Breast cancer has diverse ...

The research also combined advanced sequencing techniques to explore the interplay between genetic mutations, cell cycle dynamics, and cancer evolution, providing insights into metastatic potential.

“Will the cycle eventually catch up to patients who have gone through CAR T-cell therapy? Does innate immune dysfunction disappear with CAR T or BiTE? Interferon responses and long-term ...

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is ...

With so much at stake, nature keeps it tightly controlled in a process called the cell cycle that scientists thought they thoroughly understood. UCSF scientists discover that multiciliated cells ...